12:00 AM
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TKM-PLK1: Phase I data

Data from 9 evaluable patients with advanced solid tumors in an open-label, dose-escalation, U.S. Phase I trial showed that IV TKM-PLK1 at doses of >=0.6 mg/kg produced 1 durable partial response for >=10 months in a patient with progressive, metastatic neuroendocrine cancer, plus 3 cases of stable disease. TKM-PLK1 was generally well tolerated...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >